NASDAQ:CERT

Certara (CERT) Stock Forecast, Price & News

$17.00

-0.25 (-1.45%)

(As of 06/9/2023 ET)

Compare

Today's Range: $16.95
▼
$17.80
50-Day Range: $17.00
▼
$24.64
52-Week Range: $10.60
▼
$24.96

Volume: 1.97 million shs
Average Volume: 1.23 million shs
Market Capitalization: $2.72 billion

P/E Ratio: 188.89
Dividend Yield: N/A
Price Target: $24.25

Certara MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 42.6% Upside
$24.25 Price Target
Short Interest: Bearish
10.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.72
Based on 11 Articles This Week
Insider Trading: Selling Shares
$634,091 Sold Last Quarter
Proj. Earnings Growth: 10.81%
From $0.37 to $0.41 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

211th out of 987 stocks

Prepackaged Software Industry

42nd out of 212 stocks

3.3

Analyst's Opinion

Consensus Rating
Certara has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.25, Certara has a forecasted upside of 42.6% from its current price of $17.00.
Amount of Analyst Coverage
Certara has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.45% of the float of Certara has been sold short.
Short Interest Ratio / Days to Cover
Certara has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Certara has recently increased by 1.87%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Certara does not currently pay a dividend.
Dividend Growth
Certara does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Certara has received a 63.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Management consulting for the pharmaceutical industry", "Drug discovery software", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Certara is -0.73.

2.6

News and Social Media Coverage

News Sentiment
Certara has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Certara this week, compared to 4 articles on an average week.
Search Interest
3 people have searched for CERT on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Certara to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Certara insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $634,091.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of Certara is held by insiders.
Percentage Held by Institutions
75.45% of the stock of Certara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Certara are expected to grow by 10.81% in the coming year, from $0.37 to $0.41 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Certara is 188.89, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 143.95.
Price to Earnings Ratio vs. Sector
The P/E ratio of Certara is 188.89, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 127.08.
Price to Earnings Growth Ratio
Certara has a PEG Ratio of 1.07. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Certara has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Certara (NASDAQ:CERT) Stock

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

CERT Stock News Headlines

June 10, 2023 | americanbankingnews.com

Analysts Set Certara, Inc. (NASDAQ:CERT) Target Price at $24.25

June 9, 2023 | markets.businessinsider.com

Bank of America Securities Reaffirms Their Buy Rating on Certara (CERT)

June 10, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

June 9, 2023 | americanbankingnews.com

Certara (NASDAQ:CERT) Trading Down 9% After Insider Selling

June 7, 2023 | americanbankingnews.com

Certara, Inc. (NASDAQ:CERT) Insider Patrick F. Smith Sells 19,104 Shares of Stock

June 2, 2023 | finance.yahoo.com

Certara to Participate in the Jefferies Global Healthcare Conference

May 22, 2023 | msn.com

Looking Into Certara's Return On Capital Employed

May 17, 2023 | markets.businessinsider.com

Berenberg Bank Reaffirms Their Buy Rating on Certara (CERT)

June 10, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

May 17, 2023 | americanbankingnews.com

Richard M. Traynor Sells 5,000 Shares of Certara, Inc. (NASDAQ:CERT) Stock

May 16, 2023 | finance.yahoo.com

Reasons to Invest in Certara (CERT)

May 14, 2023 | americanbankingnews.com

Analysts Set Certara, Inc. (NASDAQ:CERT) Price Target at $24.25

May 11, 2023 | americanbankingnews.com

Certara (NASDAQ:CERT) Shares Gap Down to $23.42

May 10, 2023 | markets.businessinsider.com

Bank of America Securities Sticks to Their Buy Rating for Certara (CERT)

May 10, 2023 | marketwatch.com

Certara Reports First Quarter 2023 Financial Results

May 9, 2023 | americanbankingnews.com

Certara (NASDAQ:CERT) Issues FY23 Earnings Guidance

May 9, 2023 | finance.yahoo.com

Q1 2023 Certara Inc Earnings Call

May 9, 2023 | americanbankingnews.com

Certara (NASDAQ:CERT) Releases Earnings Results, Meets Expectations

May 9, 2023 | americanbankingnews.com

Head to Head Contrast: Certara (NASDAQ:CERT) and Information Analysis (OTCMKTS:IAIC)

May 7, 2023 | markets.businessinsider.com

Certara earnings preview: what Wall Street is expecting

May 7, 2023 | americanbankingnews.com

Certara (CERT) to Release Earnings on Monday

May 1, 2023 | finance.yahoo.com

Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

April 27, 2023 | finance.yahoo.com

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year

April 19, 2023 | americanbankingnews.com

Insider Selling: Certara, Inc. (NASDAQ:CERT) SVP Sells 5,000 Shares of Stock

April 19, 2023 | americanbankingnews.com

Brokerages Set Certara, Inc. (NASDAQ:CERT) PT at $24.25

April 16, 2023 | americanbankingnews.com

Analyzing Certara (NASDAQ:CERT) & Porch Group (NASDAQ:PRCH)

April 13, 2023 | msn.com

Stephens & Co. Initiates Coverage of Certara (CERT) with Overweight Recommendation

See More Headlines

CERT Price History

30 days | 90 days | 365 days | Advanced Chart

CERT Company Calendar

Last Earnings: 5/08/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Prepackaged software
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CERT
CUSIP: N/A
CIK: 1827090
Web: www.certara.com
Phone: 609-716-7900
Fax: N/A
Employees: 1,204
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $24.25
High Stock Price Forecast: $28.00
Low Stock Price Forecast: $19.00
Forecasted Upside/Downside: +42.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.09
Trailing P/E Ratio: 188.89
Forward P/E Ratio: 45.95
P/E Growth: 1.07
Net Income: $14.73 million
Net Margins: 4.03%
Pretax Margin: 5.07%
Return on Equity: 5.53%
Return on Assets: 3.84%

Debt

Debt-to-Equity Ratio: 0.27
Current Ratio: 3.71
Quick Ratio: 3.71

Sales & Book Value

Annual Sales: $335.64 million
Price / Sales: 8.10
Cash Flow: $0.59 per share
Price / Cash Flow: 28.95
Book Value: $6.76 per share
Price / Book: 2.51

Miscellaneous

Outstanding Shares: 159,830,000
Free Float: 155,676,000
Market Cap: $2.72 billion
Optionable: Not Optionable
Beta: 1.58

Key Executives

Dr. William F. Feehery Ph.D. (Age 52)
CEO & Director
Comp: $1.24M

Mr. M. Andrew Schemick (Age 49)
Chief Financial Officer
Comp: $568.7k

Mr. Leif E. Pedersen (Age 59)
Pres of Software
Comp: $434.11k

Dr. Robert P. Aspbury Ph.D. (Age 51)
Pres of Simcyp Division
Comp: $541.23k

Mr. Andrew Schemick
Chief Financial Officer

Prof. Amin Rostami PharmD
Ph.D., FCP, Chief Scientific Officer

Mr. Richard M. Traynor (Age 51)
Sr. VP, Gen. Counsel & Sec.

Mr. Ron DiSantis
Sr. VP of Corp. Devel.

Ms. Nicolette D. Sherman (Age 53)
Chief HR Officer

Mr. Jaap Mandema
Chief Innovation Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERT Stock - Frequently Asked Questions

Should I buy or sell Certara stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Certara in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CERT shares.
View CERT analyst ratings or view top-rated stocks.
What is Certara's stock price forecast for 2023?: 8 equities research analysts have issued 1 year price objectives for Certara's stock. Their CERT share price forecasts range from $19.00 to $28.00. On average, they expect the company's share price to reach $24.25 in the next twelve months. This suggests a possible upside of 42.6% from the stock's current price.
View analysts price targets for CERT or view top-rated stocks among Wall Street analysts.
How have CERT shares performed in 2023?: Certara's stock was trading at $16.07 on January 1st, 2023. Since then, CERT stock has increased by 5.8% and is now trading at $17.00.
View the best growth stocks for 2023 here.
When is Certara's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our CERT earnings forecast.
How were Certara's earnings last quarter?: Certara, Inc. (NASDAQ:CERT) released its quarterly earnings results on Monday, May, 8th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by $0.00. The business earned $90.30 million during the quarter, compared to analyst estimates of $91.29 million. Certara had a net margin of 4.03% and a trailing twelve-month return on equity of 5.53%. The company's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.11 earnings per share.
What ETFs hold Certara's stock?: ETFs with the largest weight of Certara (NASDAQ:CERT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Janus Henderson US Sustainable Equity ETF (SSPX), BlackRock Future Innovators ETF (BFTR), Convergence Long/Short Equity ETF (CLSE), First Trust Health Care AlphaDEX Fund (FXH), iShares U.S. Healthcare Providers ETF (IHF), SPDR S&P SmallCap 600 ESG ETF (ESIX) and SPDR S&P 600 Small Cap Growth ETF (SLYG).
What guidance has Certara issued on next quarter's earnings?: Certara updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided EPS guidance of $0.50-$0.55 for the period, compared to the consensus EPS estimate of $0.52. The company issued revenue guidance of $370.00 million-$385.00 million, compared to the consensus revenue estimate of $378.55 million.

When did Certara IPO?: (CERT) raised $500 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,400,000 shares at a price of $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair served as the underwriters for the IPO.
What is Certara's stock symbol?: Certara trades on the NASDAQ under the ticker symbol "CERT."
Who are Certara's major shareholders?: Certara's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.26%), Baillie Gifford & Co. (5.95%), William Blair Investment Management LLC (4.40%), ArrowMark Colorado Holdings LLC (3.35%), Clearbridge Investments LLC (2.43%) and JPMorgan Chase & Co. (2.31%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner, James E Cashman III, Jieun W Choe, Justin Edge, Leif E Pedersen, Mason P Slaine, Matthew M Walsh, Michael Andrew Schemick, Patrick F Smith, Richard M Traynor, Robert Aspbury, Stephen M Mclean and William F Feehery.
View institutional ownership trends.
How do I buy shares of Certara?: Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Certara's stock price today?: One share of CERT stock can currently be purchased for approximately $17.00.
How much money does Certara make?: Certara (NASDAQ:CERT) has a market capitalization of $2.72 billion and generates $335.64 million in revenue each year. The company earns $14.73 million in net income (profit) each year or $0.09 on an earnings per share basis.
How many employees does Certara have?: The company employs 1,204 workers across the globe.
How can I contact Certara?: Certara's mailing address is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. The official website for the company is www.certara.com. The company can be reached via phone at 609-716-7900 or via email at ir@certara.com.

This page (NASDAQ:CERT) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Certara (CERT) Stock Forecast, Price & News

Certara MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Certara (NASDAQ:CERT) Stock

CERT Stock News Headlines

CERT Price History

CERT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CERT Stock - Frequently Asked Questions

Overall MarketRank^™